NCT07839455Active, not recruitingPhase 2
Oral and Topical Phytocannabinoids for Psoriasis
Oral and Topical Use of Phytocannabinoids for Patients With Psoriasis Vulgaris: An Open-Label Prospective Study - CBDermis
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
Psoriasis is a chronic inflammatory skin disease that affects approximately 2% of the global population and is frequently associated with psychiatric comorbidities such as anxiety and depression. Although conventional treatments, including topical corticosteroids and biologic agents, may be effective, many patients face challenges related to treatment adherence, adverse effects, and the psychosocial impact of the disease. This open label study aims to investigate the efficacy and acceptability of medicinal cannabis formulations administered orally and topically in the management of mild to moderate psoriasis. 37 participants will be included and will use full spectrum cannabis formulations in the (1:1:1) CBD:CBG:THC ratio at a concentration of 20 mg/ml. The protocol will have a total duration of 180 days, consisting of 60 days of isolated treatment followed by 120 days of combined treatment. Efficacy will be assessed using validated instruments, including PASI, DLQI, BDI II and BAI, the Visual Analog Scale for pruritus intensity, the Cosmetic Acceptability Scale, and the Treatment Satisfaction Scale. The use of cannabis formulations is expected to promote clinical improvement of skin lesions, reduction of subjective symptoms such as pruritus and discomfort, and a positive impact on patients quality of life. This study seeks to contribute to the generation of evidence, regarding the efficacy, safety, and acceptability of therapeutic cannabis use in the dermatological context.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- First submitted
- 28 Jul 2026
- Start date
- 1 Nov 2025
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Federal University of Latin American Integration
- Diseases
- Psoriasis
- NCT number
- NCT07839455
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 37
- From 1 Nov 2025 to the primary completion date, 1 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Ongoing pharmacological treatment with unstable therapy or changes in lesion severity within the last 30 days
Other illness
- Presence of other active inflammatory dermatological diseases that may interfere with psoriasis assessment
- History of severe recurrent skin infections or active infection at screening
- History of psychosis or first-degree family history of schizophrenia or epilepsy
- Severe cardiovascular diseases
- Severe hepatic or renal diseases
Other
- Patients who do not meet the inclusion criteria
- Use of phototherapy within the last 2 months
- Pregnant or breastfeeding women
- Diagnosis of psoriatic arthritis
- Lack of availability to attend study assessments
- Refusal to sign the Informed Consent Form (ICF)
Who the study is looking for
- Clinical diagnosis of psoriasis vulgaris confirmed by a dermatologist
- Age between 18 and 65 years
- Psoriasis Area and Severity Index (PASI) ≤ 10 at screening
- Patients with clinical stability over the past 3 months, without significant changes in psoriasis condition
- Availability to attend consultations and periodic assessments during the study
- Agreement to participate and signing of the Informed Consent Form (ICF)
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Federal University of Latin American Integration Coordinator of this site? Confirm its status | Foz do Iguaçu | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.